Schonfeld Strategic Advisors LLC Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Schonfeld Strategic Advisors LLC acquired a new position in Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 1,891 shares of the company's stock, valued at approximately $308,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. raised its holdings in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in Zoetis during the 4th quarter valued at $44,000. Asset Planning Inc bought a new stake in Zoetis in the 4th quarter worth $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Zoetis in the fourth quarter valued at about $59,000. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE ZTS traded up $2.68 during trading hours on Friday, hitting $163.03. 2,391,686 shares of the company's stock traded hands, compared to its average volume of 2,510,680. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The business's fifty day moving average price is $156.49 and its two-hundred day moving average price is $165.56. The firm has a market capitalization of $72.58 billion, a P/E ratio of 29.80, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the prior year, the company posted $1.38 EPS. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ZTS. Piper Sandler increased their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Stifel Nicolaus reduced their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $212.75.

Insider Buying and Selling

In other news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.